Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors

Melanoma is a disease haunting mankind for centuries and the proofs documented in the literature can be traced back to 1600s. The incidences of metastatic melanomas are growing steadily ultimately leading to increase in the mortality rate in comparison to other cancers (Hodi et al., 2010). The initial standard therapies for metastatic melanomas were chemotherapy like dacarbazine, interleukin 2, surgery etc., but could not perform well over the time. Nearly 50% of the patients suffering from melanomas have mutation in BRAF gene (encodes B-Raf protein, a member of Raf kinase family of growth signal transduction protein kinases).

Source: Critical Reviews in Oncology Hematology - March 19, 2018 Category: Cancer & Oncology Authors: Mohd Wahid, Arshad Jawed, Raju K. Mandal, Sajad A. Dar, Naseem Akhter, Pallavi Somvanshi, Farah Khan, Mohtashim Lohani, Mohammed Y. Areeshi, Shafiul Haque Source Type: research